Clinical Trial Update: Baricitinib in CPPD - the BAPTIST Study [Phase 2]

View source ↗

Summary

Phase 2 clinical trial (BAPTIST) evaluating baricitinib for calcium pyrophosphate deposition disease and chondrocalcinosis; currently not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Calcium Pyrophosphate Deposition Disease
• Chondrocalcinosis

Drugs mentioned

• Baricitinib (baricitinib)

Snippet

Sponsor: I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio | Conditions: Calcium Pyrophosphate Deposition Disease, Chondrocalcinosis | Phase 2 | Status: NOT_YET_RECRUITING